
NFP and Alphabet's GV unit contributed to a series B round that will help the fertility and gynaecology services startup expand its brick-and-mortar outlets.
The neurodegenerative disease startup has emerged from stealth with $30m taken in a series A round co-led by GlaxoSmithKline's SR One unit.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
The SK Holdings, China Life and Legend Holdings-backed cancer and inflammatory disease drug developer has now raised more than $260m in under two years.
General Atlantic led a $75m series D round for Doctor on Demand, a virtual care provider with shareholders including GV, Qualcomm Ventures and Dignify Health.
Nikon was among the investors that helped the eye disease treatment developer close a round that pushed its overall funding to $24m.
Optum Ventures helped the prescription fulfilment platform push its total funding to more than $39m, with the cash to fund product development.
VillageMD is set to receive a total of $1bn in equity and convertible debt financing from Walgreens Boots Alliance over the next three years, giving the corporate a 30% stake.
The cancer therapy developer boosted its overall funding to more than $200m in a round that included series A backer Takeda Ventures.
Lundbeckfonden Ventures took a board seat at VarmX as part of a $36.2m round that will fund development of a treatment for spontaneous bleeding.